Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019
The operator will provide instructions on asking questions before and during the call.
Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY)
will announce results for the fourth quarter and full year ended March
31, 2019 on Friday, May 17, 2019 after the Board Meeting.
Summary of Events
| Event | Date and Time | Medium | ||
| Release of financial results | May 17th, after the Board Meeting |
Email, Media, Company website, Business Wire |
||
|
Press meet presentation |
Will be available on the Company’s website |
URL available on Company’s website, www.drreddys.com |
||
| Earnings Call | May 17th, 6:00 PM IST / 8:30 AM EDT |
Hosted by the Company (Details below) |
||
| Playback of Earnings Call | After the earnings call till May 24th, 2019 | Details below | ||
| Transcript of the Earnings call | Will be available on the Company’s website |
URL available on Company’s website, www.drreddys.com |
Earnings Call
Following the release, the management of the Company will host an
earnings call to discuss the Company’s financial performance. (Dial
In and other details given below)
Play Back
The play back will be available after the earnings call, till May 24th,
2019. For play back dial in phone No: 022 7194 5757 / 022 6663 5757, and
Playback Code is 04147.
| Conference Dial-In Numbers | ||
| Universal Access Number: |
+91 22 6280 1219
+91 22 7115 8120 |
|
|
Local Access Number:
Available all over India |
+91 70456 71221 | |
| International Toll Free Number: |
USA: 1 866 746 2133
UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
|
No password/pin number is necessary to dial in to any of the above
numbers. The operator will provide instructions on asking questions
before and during the call.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124)
(NSE: DRREDDY) (NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier
lives. Through its three businesses - Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology.
Dr Reddy’s operates in markets across the globe. Our Major markets
include – USA, India, Russia & CIS countries, and Europe. For more
information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words "may," "will," "should," "expects,"
"plans," "intends," "anticipates," "believes," "estimates," "predicts,"
"potential," or "continue" and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults, currency exchange rates, interest
rates, persistency levels and frequency/severity of insured loss events,
(ii) mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws and
regulations and in the policies of central banks and/or governments, (v)
the impact of acquisitions or reorganization, including related
integration issues.
The company assumes no obligation to update any information contained
herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190417005668/en/